特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の等温核酸増幅技術(INAAT)市場:技術、用途、地域別 - 成長、動向、予測(2018年~2023年)

Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market - Segmented by Technology, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)

発行 Mordor Intelligence LLP 商品コード 390904
出版日 ページ情報 英文 112 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.99円で換算しております。
世界の等温核酸増幅技術(INAAT)市場:技術、用途、地域別 - 成長、動向、予測(2018年~2023年) Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market - Segmented by Technology, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)
出版日: 2018年05月01日 ページ情報: 英文 112 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

世界の等温核酸増幅技術(INAAT)市場は、2018年から2023年の予測期間に10.5%のCAGRを記録する見通しです。

当レポートでは、世界の等温核酸増幅技術(INAAT)市場を調査し、市場の概要、技術・用途・地域別の市場規模の推移と予測、市場の成長要因・阻害要因ならびに市場機会・課題の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 成長要因、阻害要因、機会、課題の分析(DROC)

  • 市場の成長要因
    • 分子診断の急増
    • 慢性疾患の罹患率の上昇と高齢化
    • PCR(ポリメーラゼ連鎖反応法)と比較しINAATの採用の増加
  • 市場の阻害要因
    • PCR技術の脅威
    • 新しい診断技術の認知度の不足
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • 技術別
    • HDA法
    • NEAR法
    • LAMP法
    • SDA法
    • NASBA法
    • TMA法
    • SPIA法
    • その他
  • 用途別
    • 腫瘍
    • 研究調査
    • 診断
    • 血液スクリーニング
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • M&A分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • Alere, Inc.
  • Becton, Dickinson & Company
  • BioHelix
  • bioMerieux
  • Hologica
  • New England Biolabs
  • Nugen
  • Qiagen
  • Quidel Corporation
  • リストは網羅的ではありません

第10章 市場の将来展望

目次
Product Code: 49281

The global isothermal nucleic acid amplification technology (INAAT) market is expected to register a CAGR of 10.5%, during the forecast period, (2018-2023). North America dominates the market, due to technological advancement and growing awareness regarding INAAT technique among end-user in the region.

Rise in the Miniaturization of Nucleic Acid based Diagnostics

Miniaturization of biochemical reactions leads to major advantages, where a lower amount of valuable clinical sample and reagents is just one: approximately 1/1000 of the volume used in conventional lab setups has been shown to obtain a similar result. A smaller heat capacity allows for rapid changes in temperature beneficial for the PCR time, as well as a higher parallelism of multiple genetic samples. The benefit of isothermal amplification methods compared to PCR is the constant temperature of amplification. This will result in a high potential for a simple integration in point-of-care devices and a reduction of complexity. With increasing demand of low cost and effective solutions for diagnosis of diseases and increasing demand for point of care applications, these devices are going to witness growth in the future. Also in case of laboratories the sample size required is very small which also helps in reducing the amount of reagents required. Also, the upsurge in the molecular diagnostics market, increasing incidences of chronic diseases and aging population, and increase in the adoption of INAAT over PCR are driving the market growth.

Stringent regulatory framework

In the expanding market for medical devices and therapies, there are stringent regulatory policies in place to ensure the safety of such drugs and devices. These policies are well studied. However, while rigorous regulatory procedures guarantee the quality of the product entering the market, they delay the entry of a drug or device into the market, which could be beneficial to all patients suffering from a disease. Pre-market approval is an FDA process of scientific and regulatory review to evaluate the safety and effectiveness of drugs and devices. There have been procedures by the FDA to heighten the post-market surveillance. The FDA review process takes twice as much as time as European regulatory commissions review bodies. Hence, citizens from countries where the review process is shorter benefit more than countries with longer review processes and stringent regulations. The presence of stringent regulations is dampening the innovation in the market and hindering the growth of this market. Strict regulatory policies have resulted in a reduction of investment by drug companies in R&D of new products. Also the lack of awareness in new diagnostics technologies may induce users to stick to conventional methods, although this can be addressed with effective marketing

North America to Dominate the Market

North America dominates the Isothermal Nucleic Acid Amplification Technology (INAAT) market, owing to high incidence of chronic diseases, technological advancement in isothermal nucleic acid amplification technology (INAAT), and increasing adoption of INAAT over conventional techniques in the region. Asia Pacific is expected to grow during the forecast period, owing to factors, such as high demand in cost effective and diagnostics, less stringent regulatory scenario, and presence of huge population base.

Key Developments in the Market

March 2017: Alere Inc. a global leader in rapid diagnostic tests, announced that the U.S. Food and Drug Administration (FDA) has granted CLIA waiver for the Alere i Strep A test

Major Players: ALERE, BECTON, DICKINSON & COMPANY, BIOMERIUX, HOLOGICA, LUCIGEN, QUIDEL CORPORATION, NEW ENGLAND BIOLABS, NUGEN, QIAGEN, USTAR BIOTECHNOLOGIES, amongst others.

Reasons to Purchase this Report

Current and future global isothermal nucleic acid amplification technology outlook, in the developed and emerging markets

Analysis of various perspectives of the market with the help of Porter's five forces analysis

The segment that is expected to dominate the market

Regions that are expected to witness the fastest growth during the forecast period

Identify the latest developments, market shares, and strategies employed by the major market players

3 months analyst support, along with the Market Estimate sheet (in Excel)

Customization of the Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitute Product and Services
    • 5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Upsurge in the Molecular Diagnosis
    • 6.1.2 Increasing Incidences of Chronic Diseases and Aging Population
    • 6.1.3 Increase in the Adoption of INAAT over PCR
    • 6.1.4 Rise in the Miniaturization of Nucleic Acid Based Diagnosis
  • 6.2 Market Restraints
    • 6.2.1 Threatening Opposition from PCR Technologies
    • 6.2.2 Lack of Awareness of New Diagnostics Technologies
  • 6.3 Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 By Technology
    • 7.1.1 Helicase-dependent Amplification (HDA)
    • 7.1.2 Nicking Enzyme Amplification Reaction (NEAR)
    • 7.1.3 Loop-mediated Isothermal Amplification (LAMP)
    • 7.1.4 Strand Displacement Amplification (SDA)
    • 7.1.5 Nucleic Acid Sequence Based Amplification (NASBA)
    • 7.1.6 Transcription Mediated Amplification (TMA)
    • 7.1.7 Single Primer Isothermal Amplification (SPIA)
    • 7.1.8 Others
  • 7.2 By Applications
    • 7.2.1 Oncology
    • 7.2.2 Laboratory Research
    • 7.2.3 Diagnostics
    • 7.2.4 Blood Screening
    • 7.2.5 Others
  • 7.3 By Geography
    • 7.3.1 North America
      • 7.3.1.1 United States
      • 7.3.1.2 Canada
      • 7.3.1.3 Mexico
    • 7.3.2 Europe
      • 7.3.2.1 France
      • 7.3.2.2 Germany
      • 7.3.2.3 United Kingdom
      • 7.3.2.4 Italy
      • 7.3.2.5 Spain
      • 7.3.2.6 Rest Of Europe
    • 7.3.3 Asia-Pacific
      • 7.3.3.1 China
      • 7.3.3.2 Japan
      • 7.3.3.3 India
      • 7.3.3.4 Australia & New Zealand
      • 7.3.3.5 South Korea
      • 7.3.3.6 Rest of Asia-Pacific
    • 7.3.4 Middle East & Africa
      • 7.3.4.1 GCC
      • 7.3.4.2 South Africa
      • 7.3.4.3 Rest of the Middle East & Africa
    • 7.3.5 South America
      • 7.3.5.1 Brazil
      • 7.3.5.2 Argentina
      • 7.3.5.3 Rest of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations, and Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 Alere, Inc.
  • 9.2 Becton, Dickinson & Company
  • 9.3 BioHelix
  • 9.4 bioMerieux
  • 9.5 Hologica
  • 9.6 New England Biolabs
  • 9.7 Nugen
  • 9.8 Qiagen
  • 9.9 Quidel Corporation
  • 9.10 List Not Exhaustive

10. Future of the Market